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Abstract
Background: Tumor-associated antigens recognized by humoral effectors of the immune system
are a very attractive target for human cancer diagnostics and therapy. Recent advances in molecular
techniques have led to molecular definition of immunogenic tumor proteins based on their
reactivity with autologous patient sera (SEREX).
Methods: Several high complexity phage-displayed cDNA libraries from breast carcinomas, human
testis and breast carcinoma cell lines MCF-7, MDA-MB-468 were constructed. The cDNAs were
expressed in the libraries as fusion to bacteriophage lambda protein D. Lambda-displayed libraries
were efficiently screened with sera from patients with breast cancer.
Results: A panel of 21 clones representing 18 different antigens, including eight proteins of
unknown function, was identified. Three of these antigens (T7-1, T11-3 and T11-9) were found to
be overexpressed in tumors as compared to normal breast. A serological analysis of the 21
different antigens revealed a strong cancer-related profile for at least five clones (T6-2, T6-7, T7-
1, T9-21 and T9-27).
Conclusions: Preliminary results indicate that patient serum reactivity against five of the antigens
is associated with tumor disease. The novel T7-1 antigen, which is overexpressed in breast tumors
and recognized specifically by breast cancer patient sera, is potentially useful in cancer diagnosis.
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Background
A recent development in tumor immunology is based on
the idea that the immune system can distinguish between
normal and tumor tissues. Various studies suggest that
both the cellular and humoral components of the
immune system are able to recognize tumors (see review
of Lake et al.) [1]. The presence of natural antibodies
against cancer cells in peripheral blood of tumor patients
probably plays a protective role against tumor develop-
ment. The latest advances in molecular techniques further
support the existence of natural antibodies against cancer
antigens. The SEREX approach, based on the serological
screening of cDNA expression libraries generated from
tumor tissues of various origin, led to the molecular defi-
nition of immunogenic tumor proteins (tumor-associated
antigens, TAAs) based on their reactivity with autologous
patient sera [2]. This type of screening of a cDNA expres-
sion library is quite a laborious procedure requiring the
preparation of a large number of membrane filters blotted
with bacteriophage plaques, which are then screened with
sera from cancer patients, usually available in limited
quantity. In contrast to SEREX, phage display strategy is
based on the selection and enrichment of antigens dis-
played on the phage surface. A physical link between a dis-
played fusion protein and the DNA encoding for it makes
this phage target selectable through affinity purification.
Phage display technology has been successfully applied to
the screening of cDNA libraries from different tumors
using the antibody repertoire of cancer patients [3-6]. In
these experiments different phage display systems were
used. Some of the authors used the C-terminus of a fila-
mentous phage minor protein pVI for expression of cDNA
libraries from breast cancer cell lines T47D and MCF-7 [3]
and from colorectal cancer cell line HT-29 [5]. However,
the filamentous phage display system imposes some bio-
logical bias for the expression and display of fusion pro-
teins, since a filamentous phage-based library displays
only those recombinant proteins able to pass through the
inner bacterial membrane during filamentous phage
assembly. To overcome this potential problem the lytic
bacteriophages T7 [4] and λ [6] were used. By using these
latter systems, the phage capsid is assembled in the cyto-
plasm of bacteria and mature phage particles are released
by cell lysis. For example, Hansen and co-workers in their
studies screened a commercially available (Novagen)
human breast cancer cDNA library cloned in T7 vector [4],
identifying positive clones.
Usually cDNA libraries are generated as C-terminal
fusions. When such a library is panned on a serum, the
presence of a complex antibody repertoire gives to out-of-
frame or antisense-derived cross-reactive short peptide
sequences a good chance of being enriched. In our previ-
ous work [6] we designed a new-concept lambda vector
for the display of cDNA-encoded protein fragments as
fusion to the N-terminus of bacteriophage gpD, allowing
us to overcome this obstacle. In this vector, phage clones
display a given protein fragment on the phage surface
only when the insert's correct reading frame matches that
of gpD. The size of the cloned DNA fragments in our
libraries was adjusted to an average of 200–300 base pairs,
which is of a size reasonably sufficient to potentially
encode for a protein domain. The vast majority of out-of-
frame sequences of the above-mentioned length most
probably contains at least one in-frame stop codon. Thus,
these inserts are not expressed as D fusion, are conse-
quently not displayed on the phage surface and cannot be
selected. In such cases, phage capsid contains only wt gpD
encoded by lambda genome D gene. The N-terminal dis-
play system greatly reduces the selection of artifactual
peptides, in comparison with a C-terminal fusion library
displayed on lambda ([7] and our unpublished data).
By employing the SEREX approach numerous tumor anti-
gens from different human neoplasms were identified
[8,9]. Analysis of TAA expression in tumor samples and
normal tissue led to the identification of a group, called
cancer/testis antigens. Members belonging to this family
are aberrantly expressed in human cancers and only in
normal testis, but not in other normal tissue. For this rea-
son, in addition to tumor samples and tumor cell lines,
testicular cDNA libraries are also a convenient source of
antigens which can be identified by screening with sera
derived from tumor patients [10,11].
In the present work we report the construction of lambda-
displayed cDNA libraries from breast cancer cell lines
MCF-7, MDA-MB-468, from human breast carcinomas
and from human testis, generated according to an
improved protocol. These libraries were screened by using
sera from breast cancer patients. The list of 21 identified
antigens contains eight proteins with still unknown func-
tions. Three of the genes (T7-1, T11-3 and T11-9) were
found to be overexpressed in tumors as compared to nor-
mal breast. Recognition by human sera of five of the
selected antigens (T6-2, T6-7, T7-1, T9-21 and T9-27) was
associated with cancer diagnosis.
Methods
Tissue and serum samples
Specimens of breast carcinoma and autologous sera from
breast cancer patients (B81-B96) were obtained from M.
G. Vannini Hospital, Rome. A panel of human sera from
breast cancer patients B1-B20, B36-B80 was provided by
the Division of Medical Oncology, Federico II University
of Naples. All the human biological samples were
obtained through informed consent.BMC Cancer 2004, 4:78 http://www.biomedcentral.com/1471-2407/4/78
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Construction of λKM8, λKM10 vectors
λKM8 was constructed by cloning the oligonucleotide
duplex  KM46 5’-
CTAGTCTCCTCAGCGGCCGCGGTTCCGGTTCTGGTTC-
CGGTTCTGGTTCCGGTTCTGGT-3’ and KM47 5’-
GGCCACCAGAACCGGAACCAGAACCGGAACCAGAAC-
CGGAACCGCGGCCGCTGAGGAGA-3’ into SpeI,  NotI
sites at the 5'-end of the D gene in λKM4 vector [6]. The
resulting vector λKM8 maintains the unique SpeI and NotI
sites and encodes for a GS linker between the fusion site
and gpD, Figure 1.
The plasmid pKM7 is a derivative of pKM3 [6], which was
obtained by cloning of the oligonucleotide duplex K52
5’-
GACCGCGTTTGCCGGAACGGCAATCAGCATCGTTACT
AGTTTATTAAGCGGCCGCTAAGTGAGTG-3’ K53  5’-
AATTCACTCACTTAGCGGCCGCTTAATAAACTAGTAAC-
GATGCTGATTGCCGTTCCGGCAAACGCG-3’ into pKM3
previously digested with RsrII and EcoRI restriction
enzymes. pKM7 was digested with SpeI and NotI to obtain
pKM9, by direct cloning of the oligonucleotide duplex
KM48 5’-CTAGCGGTTCCGGTTCTGGTTCCGGTTCT-
GGTTCCGGTTCTGGCACTAGTCTCCTCAGC-3’ and
KM49 5’-GGCCGCTGAGGAGACTAGTGCCAGAACCG-
GAACCAGAACCGGAACCAGAACCGGAACCG-3’.
λKM10 was constructed by cloning pKM9, which was lin-
earized by digestion with XbaI restriction enzyme, into the
XbaI site of λDam15imm21nin5 [12]. The resulting vector
λKM10 bears unique SpeI, NotI sites at the 3'-end of the D
gene and encodes for a flexible GS linker between gpD
and the cloned protein fragment, Figure 1.
RNA extraction
mRNA from breast carcinoma cell lines MCF-7 and MDA-
MB-468 was isolated in a single step by QuickPrep Micro
mRNA Purification Kit (Amersham Pharmacia Biotech,
UK) according to manufacturer's instructions.
Tumor samples from breast carcinoma patients were
obtained as surgical specimens and immediately frozen in
liquid nitrogen. Total RNA was prepared by Total RNA
Isolation System (Promega, Madison, WI) and purified to
Poly A+ RNA using PolyATract mRNA Isolation Systems
(Promega).
Total RNA from normal testis was purchased from Gen-
pak, UK (# 061023). Total RNA from normal breast (pool
of 3) was purchased from Stratagene, La Jolla, CA (#
735044).
cDNA library construction
From 1 to 5 µg of the purified poly(A)+ RNA from cell
lines or human tissues were used to synthesize cDNA by
random priming, using TimeSaver cDNA Synthesis Kit
(Amersham Pharmacia Biotech, Piscataway, NJ, USA).
RNasin Ribonuclease Inhibitor (Promega) was added to
first-strand synthesis reaction.
A mixture of the following oligonucleotides (130 pmol):
K64 (5'-GCGGCCGCTGGNNNNNNNNN-3'), K79 (5'-
GCGGCCGCTGGCNNNNNNNNN-3'), and K81 (5'-
GCGGCCGCTGGCANNNNNNNNN-3') was used for
priming. They all carry a NotI site (underlined) at their 5'
end, and a random sequence of nine nucleotides at their
3' end, positioned in the three possible reading frames.
The second strand was synthesized by nick translation
according to the manufacturer's instructions.
One hundred ng of ds cDNA were randomly primed with
25 pmol of oligonucleotide K56 (5'-GGCCGGCCAAC-
NNNNNNNNN-3'), constituted by a constant sequence at
the 5' end, and a random 3'sequence. The reaction mix-
ture was purified by QIAgen QIAquick columns.
Approximately 0,2 ng of the above randomly primed ds
cDNA was amplified by PCR with biotinylated primers:
K59 (bio-5'-GCACTAGTGGCCGGCCAAC-3'), K60 (bio-
5'-GCACTAGTCGGCCGGCCAAC-3'), K61 (bio-5'-
GCACTAGTCGGGCCGGCCAAC-3') and K65 (bio-5'-
GGAGGCTCGAGCGGCCGCTGG-3'). K59, K60 and K61
carry the same constant sequence of K56 positioned in the
three possible frames with respect to a SpeI site (under-
lined) allowing directional cloning. K65 carries a NotI site
(underlined), that anneals to the 5' end of the reverse
strand of cDNA.
PCR product was purified with QIAquick PCR purification
kit (QIAGEN, Germany), filtered by Microcon-100 col-
umns (Millipore, Bedford, MA) to reduce the number of
small fragments and additionally fractionated by 6%
Cloning sites of λKM8 and λKM10 vectors Figure 1
Cloning sites of λKM8 and λKM10 vectors.BMC Cancer 2004, 4:78 http://www.biomedcentral.com/1471-2407/4/78
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PAGE. DNA smear, corresponding to 300–1000 base-pair
fragments, was cut and eluted from gel according to stand-
ard procedure [13].
After digestion with SpeI and NotI enzymes, in order to
remove the biotinylated extremities and uncut fragments,
a 20-minute incubation with streptavidin M-280 Dyna-
beads (DYNAL, Norway) was performed. After additional
filtration on Microcon-100 the insert was cloned in λKM8
or λKM10 vectors.
The vector was digested with SpeI,  NotI enzymes and
dephosphorylated. For each library 5 ligation mixtures,
each one containing 0.5 µg of vector and about 3 ng of
insert, were performed. After overnight incubation at 4°C
the ligation mixtures were packaged in vitro by lambda
packaging extract (Stratagene, La Jolla, CA). BB4 cells were
infected by lambda and plated in top-agar on 100 (15 cm)
NZY plates. After overnight incubation phages were eluted
from the plates with SM buffer, purified, PEG/NaCl pre-
cipitated [13] and stored at -80°C in SM buffer, 7%
DMSO.
Affinity selection
Two µl of human serum were preincubated with 10 µl of
BB4 bacterial extract and 10 µl of UV-killed lambda phage
in 1 ml of blocking buffer (3% BSA, 1X PBS, 10 mM
MgSO4, 1% Triton) for 30 minutes at 37°C under gentle
agitation. 1010 pfu of lambda library were then added to
the preincubated mixture for a further incubation of 1 hr.
Magnetic beads (100 µl), linked to Protein A (Dynabeads
Protein-A, Dynal, Norway) were washed twice with the
blocking solution. Mixture of library with serum was incu-
bated with the beads for 10 min at RT under agitation. The
beads were washed 10 times with 1 ml of washing solu-
tion (1X PBS, 1% Triton, 10 mM MgSO4). The bound
phages were recovered by infection of 600 µl BB4 cells
added directly to the beads. After a 20-minute incubation
10 ml of molten NZY-top agar (48°C) was added to the
mixture of beads with infected cells and immediately
poured onto NZY plates (15 cm). Next day the phage par-
ticles were harvested by incubation of the plates under agi-
tation with 15 ml of SM buffer for 4 hours at 4°C. The
phage particles were purified by PEG/NaCl precipitation
and stored in 1/10 of initial volume of SM with 0.05%
NaN3 at 4°C.
Analysis of gene expression by PCR
Five hundred ng of poly(A)+ RNA from breast carcinomas
or normal tissue were used to synthesize full-length cDNA
by SMART cDNA library construction kit (Clontech, Palo
Alto, CA). For maximum sensitivity specific primers for
the different genes were designed to amplify sequences
located near the 3' end of gene's transcript. Twenty-five
cycles of PCR were performed from 1 µl of each cDNA
template, normalized through PCR amplification of the β-
actin gene.
Results
Construction of the libraries
Lambda libraries were constructed by directional cloning
of randomly primed cDNA from human breast carcinoma
cell lines MCF-7 and MDA-MB-468, from human breast
carcinomas or from human testis into the phage display
vector λKM8 to generate fusions with the N-terminus of
gpD (see list of libraries in Table 1). Only library T6 was
built like C-terminal fusions with protein D by cloning
cDNA into λKM10 vector. λKM8 and λKM10 are deriva-
tives of λKM4 vector [6] obtained by introducing a flexible
GS-linker between the displayed protein and gpD (Fig. 1).
The insert size in the majority of the clones in the libraries
ranged from 100 to 400 bp (Fig. 2). Only a tiny fraction of
out-of-frame clones of this length do not contain stop
codons, and are therefore displayed in the libraries con-
structed as N-terminus fusions, thus greatly reducing the
probability of the selection of mimotopes.
Selection of tumor-associated antigens
The scheme of TAA identification is shown in Figure 3.
Typically, one or two rounds of biopanning, performed
according to the selection protocol described in Materials
and Methods, were sufficient to obtain 2–50% of positive
clones in the following immunoscreening procedure.
Then, the identified phage clones were tested with a panel
Table 1: Lambda display libraries list.
Library name Point of fusion with gpD Source of cDNA Library complexity
T5 N-terminus MCF-7 + MDA-MB-468 1.7 × 107
T6 C-terminus MCF-7 + MDA-MB-469 3.4 × 107
T7 N-terminus Human breast carcinoma (patient 
B81)
1.5 × 106
T9 N-terminus Human breast carcinoma (patient 
B84)
2.3 × 107
T11 N-terminus Human testis 1.3 × 107BMC Cancer 2004, 4:78 http://www.biomedcentral.com/1471-2407/4/78
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of positive and negative human sera by picking the clones
in arrayed order on the bacterial lawn, blotting onto nitro-
cellulose membrane and probing with a number of differ-
ent sera as previously described [6]. The nucleotide
sequences of 21 clones that exhibited specific or preferen-
tial reactivity with sera from breast tumor patients as com-
pared to sera from healthy donors were identified, and
their nucleotide sequences were determined (Table 2 [see
Additional file 1]).
Serological analysis of tumor antigens
Phage lysates were prepared from all the selected clones as
previously described [6] and tested in ELISA first with a
collection of negative, and subsequently, with positive
sera (Table 2 [see Additional file 1]). All the antigens
tested reacted exclusively or preferentially with sera from
breast cancer patients. Eight of the antigens reacted only
with the patient serum used in the corresponding selec-
tion. Five antigens had cancer-related profile of reactivity,
P < 0.05 (T6-2, T6-7, T7-1, T9-21 and T9-27). The other
antigens either reacted with a low percentage of cancer
sera, or the total panel of the tested sera was too small to
offer any clear conclusion.
Sequence analysis of selected cDNA clones
Twenty-one positive clones were found to encode frag-
ments from 18 different gene products, such as 4 clones
(T5-9, T9-21, T9-27, T11-7) showing homology to differ-
ent regions of the same reverse transcriptase gene (Figure
4). Most of the clones correspond to known gene products
in the correct orientation and reading frame, with the
exception of clone T5-18 encoding myc oncogen in an
alternative frame. Several of these known gene products,
such as reverse transcriptase homolog (clones T5-9, T9-21,
T9-27, T11-7), protein kinase C-binding protein (T6-1),
trap ankyrin repeat (T11-3), heat shock protein apg-2
(T11-13), have been previously identified by SEREX
[9,14-17]. Eight of the sequences listed in Table 2 [see
Additional file 1] encode for proteins with unknown
functions.
Cancer-specific expression of selected tumor antigens
Expression patterns for several of the selected genes were
analyzed by semi-quantitative PCR from SMART cDNA
Insert length distribution Figure 2
Insert length distribution. Forty-eight random clones 
from T5 library were amplified by PCR using a couple of 
primers on the sides of insert. Size of inserts was calculated 
according to their electrophoretic mobility in 3% agarose gel.
Scheme of selection strategy leading to TAA identification Figure 3
Scheme of selection strategy leading to TAA identifi-
cation. A phage-displayed tumor cDNA library is preincu-
bated with patient serum. TAA-specific antibodies bind to 
antigens exposed on the phage surface. Abs-phage complex is 
captured by protein A-coated solid support (ELISA plate or 
dynebeads). Non-bound phage are washed away. Bound 
phage are eluted by infection of added bacteria and amplified. 
Positive clones are isolated by immunoscreening procedure 
and then picked in ordered array on a bacterial lawn, trans-
ferred to nitrocellulose membrane and probed with different 
positive and negative sera.BMC Cancer 2004, 4:78 http://www.biomedcentral.com/1471-2407/4/78
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template. It has been previously shown [18], by compar-
ing the expression level of target genes in SMART PCR-
amplified cDNAs and their corresponding total RNAs,
that SMART cDNA accurately reflects gene expression pat-
terns found in total RNA. We normalized the panel of
cDNAs from ten different breast carcinomas, one
metastasized lymph node, normal breast, normal testis
and peripheral blood lymphocytes from healthy donors,
by PCR amplification of a housekeeping gene, β-actin
(Figure 5). Three of the identified antigens, fucosyltrans-
ferase (T6-7), Zinc finger protein 258 (T11-6), and p53-
binding protein (T1-52) [6], were ubiquitously expressed
in all the tumor and normal tissue samples tested (Figure
5A). Some of the antigens, T5-15 (KIAA1735), T5-13
(Sos1), T11-5 (hypothetical protein MGC4170) were
found to be downregulated in many tumors (Figure 5B).
T11-9 (hypothetical protein AF225417) was
overexpressed in 50% of the primary tumors and the
unique metastasized lymph node tested. T11-3 (trap
ankyrin repeat) was overexpressed in most of the tumors
Four identified antigen sequences with partial homology to reverse transcriptase homolog Figure 4
Four identified antigen sequences with partial homology to reverse transcriptase homolog. Peptide sequence is 
reported in single-letter code. Identical amino acids in the selected clones and reverse transcriptase homolog are represented 
by a dash. These clones were isolated from libraries of different origin. Clones T9-21 and T9-27, isolated from solid tumor 
library, had significantly high frequency of reactivity with sera from breast cancer patients.BMC Cancer 2004, 4:78 http://www.biomedcentral.com/1471-2407/4/78
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tested in comparison with normal breast, although it was
also transcribed in testis and normal lymphocytes (Figure
5C). T7-1 (KIAA1288) was found to be overexpressed in
50% of the primary breast carcinomas and in the metasta-
sis specimen tested. In order to obtain an evaluation of the
accuracy of the method used for the analysis of gene
expression, we performed PCR amplification of neu/
HER2, a known tumor marker overexpressed in breast
cancer. We observed that neu/HER2 is overexpressed in 2
primary tumors among the 7 tested (≈29%) in accordance
with the literature on breast carcinoma [19,20].
Discussion
In the present study we report the construction of MCF-7
and MDA-MB-468 cell lines, breast carcinoma and testis
cDNA phage-displayed libraries expressed as fusions to
bacteriophage lambda gpD. The new phage vectors bear a
flexible GS linker between the cloned protein domain and
protein D, so as to facilitate lambda head assembly. More-
over, a new efficient protocol to synthesize cDNA was
applied. We primed cDNA synthesis on mRNA template
with random oligonucleotides containing a constant 5'
end. After complete synthesis of double-stranded cDNA, a
second round of random priming was applied to generate
oriented fragments of cDNA suitable for library construc-
tion. This protocol, in comparison with previous version,
increases the presence of authentic protein domains in the
library twofold, because of correct cDNA orientation.
Moreover, some of the clones isolated from our previous
libraries were results of chimerical fusion of two or more
different genes, generated through double random
priming on ds cDNA template. The new protocol has
reduced this problem significantly.
We also confirmed the advantage of N-terminal fusion for
domain library construction in phage display vectors for
screening with sera, because a significant amount of false
positive cross-reactive clones, containing stop codons
downstream of the fusion site giving rise to short mimo-
tope sequences, were selected from the C-terminal fusion
library (T6). Only 4 clones with specific tumor-related
reactivity were isolated from the T6 library. However, C-
terminal fusion might allow efficient display and selec-
tion for some antigenic C-terminal protein domains. In
fact, the C-terminal fragment of fucosyltransferase (clone
T6-7) was isolated from the T6 library.
The panel of selected TAAs in Table 2 [see Additional file
1] contains several functionally defined gene products,
previously unknown as tumor antigens. AKAP450 and
Sos1 proteins, corresponding to clones T5-8 and T5-13,
are intracellular components of the signal transduction
pathway. Sos1 is a well-known guanine nucleotide
exchange factor for Ras oncogene [21]. Transgenic mice
expressing a dominant form of Sos in basal keratinocytes
cDNA-PCR analysis of gene expression was done using spe- cific sequence primers Figure 5
cDNA-PCR analysis of gene expression was done 
using specific sequence primers. We used SMART 
cDNAs from 7–10 different tumor samples (patients B84, 
B85, B87, B89, B90, B91, B92, B93, B95, B96) as template, 
from single metastasized lymph node indicated as LMB82 
(patient B82) and from normal breast, normal testis, lym-
phocytes from healthy donors. cDNAs were normalized by 
amplification of β-actin gene. There are agarose gels with 
ubiquitously-expressed genes in Figure 5A, underexpressed 
genes in Figure 5B, overexpressed ones in Figure 5C.BMC Cancer 2004, 4:78 http://www.biomedcentral.com/1471-2407/4/78
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develop skin papillomas with 100% penetrance [22].
Moreover, a Sos1 mutant, lacking four functionally
important proline-rich (SH3 binding) regions was
reported to be responsible for gingival fibromatosis [23].
AKAP450 is a member of the A-kinase anchor proteins
family. It is located in the centrosome [24], and acts as a
microtubule nucleation site [25] and as a scaffold for pro-
teins involved in mitotic process [26].
Other selected antigens with known or predicted intracel-
lular location are alpha-6-fucosyltransferase (clone T6-7)
and zinc finger protein 258 (ZNF258, clone T11-6).
Alpha-fucosyltransferase catalyzes the transfer of GDP-
fucose to oligosaccharide chains linked to proteins, lipids
and sugars [27] and resides in the luminal compartment
of trans-Golgi vesicles [28]. The predicted protein product
ZNF258 contains zinc-binding motif repeats [29]. If
ZNF258, together with structural homology, also shares
biological properties with zinc finger proteins, thus recog-
nizing and interacting with DNA, it should have a nuclear
localization. The presence on our antigen list of proteins
with predicted intracellular residence is in agreement with
findings from the other groups [30,5] and is related to
possible tissue necrosis and cell lysis associated with
tumor growth.
The human myc oncogene is transcribed from four alter-
native promoters giving rise to mRNAs for Myc1, Myc2,
MYCHEX1 and 5'ORF [31]. Clone T5-18 is the result of
the translation of an alternative frame to Myc1, Myc2 and
does not correspond to any known protein product of
myc oncogene transcription. It is not clear whether selec-
tion of this clone is an artifact of the experiment, or the
result of an aberrant genome rearrangement in the tumor
cells used for library construction.
Among isolated antigens, there are 4 clones (T5-9, T9-21,
T9-27 and T11-7) having between 55–91% sequence
identity with that of a reverse transcriptase homolog
(Figure 4). Viral antigens corresponding to human endog-
enous retrovirus were previously isolated from renal can-
cers and melanomas by SEREX [9]. It is interesting to note
that all these clones, isolated with sera from breast cancer
patients, derive from libraries constructed with cDNA
from every different origin utilized: i.e. cell lines (T5),
solid tumor (T9), testis (T11). We have no explanation for
the transcription of reverse transcriptase gene in normal
testis tissue.
Eight proteins in the tumor antigen panel are unknown,
or hypothetical proteins with unknown functions (T5-2,
T5-15, T5-19, T6-2, T6-6, T7-1, T11-5, T11-9). The four
underlined gene products from the list in parenthesis were
analyzed for mRNA expression in tumors and normal
breast tissue. The mRNA expression levels were analyzed
by PCR from SMART-cDNA template in 7–10 breast can-
cer specimens, one metastasized lymph node, normal
breast, testis and peripheral lymphocytes from healthy
donors. Two of these 4 unknown antigens and T11-3 were
found to be frequently overexpressed in breast cancer. In
particular clone T7-1, which was classified as encoding for
an unknown protein since it has 100% identity only with
KIAA1288 from EST database, was found to be overex-
pressed in breast carcinomas. This finding, together with
the good reactivity of T7-1 protein with sera from tumor
patients, identifies this antigen among the most promis-
ing targets for diagnosis of the disease.
In contrast to the other antigens, which are overexpressed
in breast cancer, mRNAs of T5-13, T5-15 and T11-5
appear to be underexpressed in 50–90% of breast cancer
specimens, in comparison with normal breast tissue. How
the immune system succeeds in responding to such anti-
gens is still not clear. However, this finding is common to
several SEREX-defined antigens, such as LU-12 [32], REN-
9, REN-10 [33] and BR-41 [15], representing a group of
TAAs deleted or downregulated in tumors. Lu-12, REN-9,
Ren-10 map within cancer tumor suppressor gene locus at
chromosome 3p21.3, a region often deleted in small cell
lung cancer as well as in renal cancer. Downregulated anti-
gen BR-41 was identified as SNT-1, a membrane-associ-
ated adaptor protein interacting with Sos1 [15]. In the
present work we show that Sos1 (T5-13) is also downreg-
ulated in 50% of breast cancer samples. The downregu-
lated antigens T11-5, T5-13 (Sos1), and T5-15 do not react
with sera from patients B82-B96 analyzed for tumor
mRNA expression. Furthermore, tumor biopsies from
patients with good response for these antigens were not
available for expression analysis. Thus, at present, it is not
possible to determine whether T11-5, T5-13 (Sos1), and
T5-15 are normally expressed, or downregulated, in
patients showing an immune response for the corre-
sponding antigen.
Sequence comparison of T11-5 and T5-15 clones with the
EST database revealed identity with the hypothetical pro-
teins MGC4170 and KIAA1735. We have derived the aa
sequence of the corresponding ORFs and predicted the
whole sequence architecture by computer analysis using
the SMART program http://smart.embl-heidel
berg.de[34,35]). MGC4170 encodes for two NL domains,
while KIAA1335 encodes for a 389 aa protein bearing a
DIX domain at the carboxy-terminus. The presence of
such structural domains indicates that both of these still
unknown proteins (corresponding to clones T11-5 and
T5-15), which we found downregulated in several tumor
specimens, may be involved in the signal transduction
machinery.BMC Cancer 2004, 4:78 http://www.biomedcentral.com/1471-2407/4/78
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In spite of the fact that several promising antigens were
identified from cDNA library constructed from testis
mRNA, none of the antigens derived from testis or other
libraries could be classified as specific testis/cancer (CT)
antigen, because of their low expression in testis (T11-9,
T7-1) or expression in other tissues as well.
In this work we analyzed the frequency of the immune
response to the 21 identified antigens by using a panel of
sera from tumor patients and healthy donors. In general,
we observed a low frequency of serum reactivity with the
antigens, which was expected and is similar to that of the
vast majority of SEREX-identified clones [36]. A signifi-
cant number of sera from tumor patients, in comparison
with healthy individuals, efficiently recognized five of the
identified antigens (T6-2, T6-7, T7-1, T9-21, T9-27).
Clones T9-21 and T9-27, isolated from breast carcinoma
library, respectively show 70% homology (55% identity)
and 62% homology (68% identity) to reverse tran-
scriptase homolog (PO8547). T7-1 is a protein having an
unknown function, which was found to be overexpressed
in breast carcinoma.
Taken together, these results lead us to believe that analy-
sis of a complex panel of serologically-defined TAAs, with
very large panels of sera from patients classified according
to clinical parameters, i.e., age of patient, stage, extent and
outcome of disease, etc. could lead to a much clearer
understanding of the role, specificity and significance of
the immune response versus disease in cancer patients.
Conclusions
We demonstrated that a lambda display-based approach
permits the efficient identification of tumor antigens,
potential immunological targets in breast cancer. The list
of 21 antigens identified in this work contains eight pro-
teins of still unknown function. Three of the genes (T7-1,
T11-3, T11-9) were found to be overexpressed in tumors
as compared to normal breast. Five of the selected anti-
gens (T6-2, T6-7, T7-1, T9-21, T9-27) were recognized spe-
cifically by breast cancer patient sera.
List of abbreviations
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